Kupferman Michael E, Myers Jeffrey N
Department of Head and Neck Surgery, M. D. Anderson Cancer Center of the University of Texas, 1515 Holcombe Boulevard, Unit 441,Houston, TX 77030, USA.
Otolaryngol Clin North Am. 2006 Apr;39(2):229-47. doi: 10.1016/j.otc.2005.11.003.
Significant advances have been made in understanding the mechanisms that contribute to carcinogenesis in OCSCC. This progress has led to the development of therapeutic strategies that target dysregulated processes in the tumor microenvironment (Fig. 11) [72]. The introduction of angiogenesis inhibitors, growth factor receptor tyrosine kinase inhibitors, and cell cycle regulators into clinical trials for the management of OCSCC has resulted from the great strides made in the understanding of tumor biology. It is important for those caring for patients who have OCSCC to have a firm background in tumor biology, because many future therapies will be based on this complex panorama of cellular physiology.
在理解导致口腔鳞状细胞癌（OCSCC）发生癌变的机制方面已经取得了重大进展。这一进展促使了针对肿瘤微环境中失调过程的治疗策略的发展（图11）[72]。对肿瘤生物学认识的巨大进步使得血管生成抑制剂、生长因子受体酪氨酸激酶抑制剂和细胞周期调节剂被引入到OCSCC治疗的临床试验中。对于护理OCSCC患者的人员来说，拥有坚实的肿瘤生物学背景很重要，因为许多未来的治疗将基于这种复杂的细胞生理学全景。
